NTHU Scientists Take a “Spin” onto the Next Generation MRAM
17.4.2019 19:30:00 EEST | Business Wire | Press release
Magnetoresistive random access memory (MRAM) is the forerunning candidate for the next generation digital technology. However, manipulating MRAM efficiently and effectively has been challenging. A revolutionary breakthrough was recently achieved by an interdisciplinary research team based at National Tsing Hua University (NTHU) in Taiwan, led by Prof. Chih-Huang Lai and Prof. Hsiu-Hau Lin. By adding a layer of platinum, only a few nanometers thick, it generates spin current to switch the pinned magnetic moments at will – a task that has never been accomplished before.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190417005048/en/
Professor Lai Chih-huang (left) and Lin Hsiu-hau of NTHU using hand gestures to represent the 0-1 concept in digital memory. (Photo: National Tsing Hua University)
From mobile phones to computers, wearable devices, the Internet of Things, and smart city operations, data processing and storage are essential. To allow faster reading and writing, less power consumption and retaining data through a power outage, MRAM stands out in the keen competitions. Lai and Lin’s breakthrough, published in Nature Materials recently, adds wings to MRAM technology and attracts attentions from both industry and academy.
Steering spin currents in MRAM
At present, information processing in digital devices is mainly carried out using dynamic random access memory (DRAM), but it consumes significant power and faces serious hurdles when reduced in size.
DRAM utilizes the charges of electrons. “But, electrons have both charge and spin.” Lai said, “Why can’t one work with electron spins to manipulate MRAM?” To put the idea into practice, Lai and Lin formed an interdisciplinary research team with doctoral students Bohong Lin and Boyuan Yang.
Lin explained that the structure of MRAM is like a sandwich. The upper layer consists of a freely flipping magnet, in charge of data computation, while the bottom layer consists of a fixed magnet, responsible for data storage; and these two layers are separated by an oxide layer.
The challenge is to switch these layers of different natures by electrical means. After a long series of experiments, they found the key ingredient: a nanometer layer of platinum. Due to spin-orbit interactions, the electric current drives the collective motion of electron spins first. The spin current then switches the pinned magnetic moment effectively and precisely.
Spintronics blazing hot
In recent years, NTHU has been promoting cross-disciplinary cooperation, such as the MRAM research conducted by the physicist Lin and the materials expert Lai, who have learned to work together seamlessly.
Major international companies all participate in the competition of MRAM development, including Samsung, Intel, and TSMC. It’s likely that mass production of high-density MRAM will begin sometime this year, a development where the research team led by Lai and Lin has played a key role.
The research team is currently extending their groundbreaking discovery to other structures, and their ongoing findings are expected to have major impacts on the development of memory industry. In Lai’s view, the development of MRAM technology is going to have a decisive influence on the future competitiveness of Taiwan's semiconductor industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190417005048/en/
Contact information
Media:
Holly Hsueh
Executive
Officer, Division of Public Affair
National Tsing Hua University
Tel:
(886)3-5162006
Mobile: (886)932-152535
Email: hoyu@mx.nthu.edu.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
